We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) closed the most recent trading day at $1.24, moving -3.88% from the previous trading session. This change lagged the S&P 500's 0.52% gain on the day. Elsewhere, the Dow gained 0.63%, while the tech-heavy Nasdaq added 0.48%.
Shares of the maker of genetic analysis technology have appreciated by 33.86% over the course of the past month, outperforming the Medical sector's gain of 1.88%, and the S&P 500's gain of 4.27%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company is predicted to post an EPS of -$0.18, indicating a 10% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $36.46 million, up 1.26% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.64 per share and revenue of $155.12 million. These totals would mark changes of +22.89% and +0.72%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 4.5% upward. At present, Pacific Biosciences of California boasts a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 182, finds itself in the bottom 27% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Pacific Biosciences of California (PACB - Free Report) closed the most recent trading day at $1.24, moving -3.88% from the previous trading session. This change lagged the S&P 500's 0.52% gain on the day. Elsewhere, the Dow gained 0.63%, while the tech-heavy Nasdaq added 0.48%.
Shares of the maker of genetic analysis technology have appreciated by 33.86% over the course of the past month, outperforming the Medical sector's gain of 1.88%, and the S&P 500's gain of 4.27%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company is predicted to post an EPS of -$0.18, indicating a 10% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $36.46 million, up 1.26% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.64 per share and revenue of $155.12 million. These totals would mark changes of +22.89% and +0.72%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Pacific Biosciences of California. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 4.5% upward. At present, Pacific Biosciences of California boasts a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 182, finds itself in the bottom 27% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.